Researchers at MU, MURR, and the Truman Memorial Veterans’ Hospital have published a new study evaluating the radioisotopes technetium and rhenium, coupled with the chelators NOTA and NODAGA, as theranostic agents for diagnosing and treating certain cancers.
The study, published in the journal Molecular Imaging and Biology found that 99mTc combined with the therapeutic radiorhenium isotopes, 186Re and 188Re, can be utilized in the development of theranostics for single photon emission computed tomography (SPECT) diagnostic imaging (99mTc) and targeted radiotherapy (186Re, 188Re) of gastrin-releasing peptide receptor (GRPR)-positive cancers.
Due to the encouraging results of this preclinical evaluation, additional studies are recommended by the researchers to explore treatment of GRPR-positive cancers using this approach.
Read more here.
Citation: Makris, G.; Bandari, R. P.; Kuchuk, M.; Jurisson, S. S.; Smith, C. J.; Hennkens, H. M. Development and Preclinical Evaluation of 99mTc- and 186Re-Labeled NOTA and NODAGA Bioconjugates Demonstrating Matched Pair Targeting of GRPR-Expressing Tumors. Mol. Imaging Biol., 2020, online ahead of print. https://doi.org/10.1007/s11307-020-01537-1